MEDNAX, Inc. (now Pediatrix Medical Group) — Q3 2012 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2012. The filing identifies the registrant as MEDNAX, Inc.; the company name in the request differs from the filing’s stated name.
Business context
MEDNAX provided newborn, maternal-fetal, pediatric subspecialty and anesthesia physician services through affiliated practices. Results include acquired practices from their respective acquisition dates. During the first nine months of 2012, the company acquired 10 physician group practices for total consideration of $205.7 million.
Financial performance
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Net patient service revenue | $473.1 million | $407.7 million | $1,345.3 million | $1,183.4 million |
| Income from operations | $107.4 million | $95.0 million | $286.5 million | $263.9 million |
| Operating margin | 22.7% | 23.3% | 21.3% | 22.3% |
| Net income | $65.9 million | $58.2 million | $174.8 million | $159.6 million |
| Diluted EPS | $1.32 | $1.19 | $3.53 | $3.28 |
- Revenue increased 16.1% in Q3 and 13.7% year to date. Acquisitions accounted for $55.5 million of Q3 growth and $125.1 million of nine-month growth; same-unit revenue rose 2.5% and 3.2%, respectively.
- Same-unit growth reflected increased patient-service volumes and modest reimbursement improvements, partly offset by a higher share of patients in lower-paying government programs.
- Operating income and net income rose, but operating margins fell 62 basis points for Q3 and 100 basis points year to date, reflecting higher operating expenses and the mix of acquired practices.
- Net cash from operations was $219.7 million for the nine months, compared with $180.9 million in 2011. Investing activities used $209.4 million, primarily for acquisitions; financing activities provided $37.2 million.
Financial position and liquidity
- At September 30, cash and cash equivalents were $66.1 million, short- and long-term investments totaled $46.3 million, and working capital was $157.9 million.
- Accounts receivable, net, was $250.5 million. Days sales outstanding improved to 48.7 days from 52.3 days at December 31, 2011.
- Outstanding line-of-credit borrowings were $48.0 million under a $500 million revolving facility; letters of credit reduced stated availability to $446.5 million. The company reported compliance with covenants and expected compliance through 2012.
- Management expected operating cash flow, cash on hand and available credit to fund working capital, anticipated acquisitions, capital expenditures and obligations for at least the next 12 months.
Outlook, commentary and risks
- No specific revenue or earnings guidance was provided. Management described expectations for continued acquisition activity and potential practice improvements through contracting, collections, growth initiatives and operating efficiencies.
- Management warned that economic weakness could increase the proportion of government-program patients, whose reimbursement is substantially lower than commercial rates. State budget pressures could also reduce or delay Medicaid funding.
- The effects of healthcare reform remained uncertain, including implementation of regulations and potential changes to Medicaid reimbursement. The filing noted a proposed rule concerning Medicare-rate payments for certain eligible primary-care services, but adoption was uncertain.
- Professional liability exposure is partly self-insured through a captive subsidiary. The recorded total liability for professional liability risks was $137.5 million; insurance may not cover future unfavorable claims in full. Government audits and investigations and malpractice or other litigation could have material adverse effects, though outcomes were not considered predictable.
- A 1% interest-rate change on the $48.0 million line-of-credit balance would affect annual pretax income by approximately $0.5 million. The filing reported no material change to previously disclosed risk factors.
- Disclosure controls were assessed as effective at the reasonable-assurance level; no materially affecting change in internal control over financial reporting was reported for the quarter.
Investor verification priorities
- Confirm the extent to which reported growth and future results depend on acquired practices versus same-unit performance, and whether anticipated acquisition synergies materialize.
- Track operating margins, physician compensation costs and reimbursement mix, particularly the impact of government-program exposure.
- Review acquisition spending, contingent consideration, goodwill and integration outcomes; acquisitions added $189.8 million of goodwill in the nine-month period.
- Monitor receivable collections and DSO, professional-liability reserves and insurance adequacy, and any material developments in audits, investigations or litigation.
- Check line-of-credit covenant compliance, borrowing costs and liquidity needs as acquisition activity continues.